دورية أكاديمية

Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study.

التفاصيل البيبلوغرافية
العنوان: Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study.
المؤلفون: Lainez, Nuria, García-Donas, Jesús, Esteban, Emilio, Puente, Javier, Sáez, M Isabel, Gallardo, Enrique, Pinto-Marín, Álvaro, Vázquez-Estévez, Sergio, León, Luis, García-Carbonero, Icíar, Suárez-Rodríguez, Cristina, Molins, Carmen, Climent-Duran, Miguel A, Lázaro-Quintela, Martín, González Del Alba, Aranzazu, Méndez-Vidal, María José, Chirivella, Isabel, Afonso, Francisco J, López-Brea, Marta, Sala-González, Nuria, Domenech, Montserrat, Basterretxea, Laura, Santander-Lobera, Carmen, Gil-Arnáiz, Irene, Fernández, Ovidio, Caballero-Díaz, Cristina, Mellado, Begoña, Marrupe, David, García-Sánchez, José, Sánchez-Escribano, Ricardo, Fernández Parra, Eva, Villa Guzmán, José C, Martínez-Ortega, Esther, Belén González, María, Morán, Marina, Suarez-Paniagua, Beatriz, Lecumberri, María J, Castellano, Daniel
سنة النشر: 2016
المجموعة: Sistema Sanitario Público de Andalucía (SSPA): Repositorio
مصطلحات موضوعية: Aged, Antineoplastic Agents, Carcinoma, Renal Cell, Female, Guideline Adherence, Humans, Kidney Neoplasms, Male, Middle Aged, Molecular Targeted Therapy, Neoplasm Metastasis, Practice Guidelines as Topic, Spain
الوصف: The impact of such recommendations after their implementation of guidelines has not usually been evaluated. Herein, we assessed the impact and compliance with the Spanish Oncology Genitourinary Group (SOGUG) Guidelines for toxicity management of targeted therapies in metastatic renal cell carcinoma (mRCC) in daily clinical practice. Data on 407 mRCC patients who initiated first-line targeted therapy during the year before and the year after publication and implementation of the SOGUG guideline program were available from 34 Spanish Hospitals. Adherence to SOGUG Guidelines was assessed in every cycle. Adverse event (AE) management was consistent with the Guidelines as a whole for 28.7% out of 966 post-implementation cycles compared with 23.1% out of 892 pre-implementation cycles (p = 0.006). Analysis of adherence by AE in non-compliant cycles showed significant changes in appropriate management of hypertension (33% pre-implementation vs. 44.5% post-implementation cycles; p Slight but significant improvements in AE management were detected following the implementation of SOGUG recommendations. However, room for improvement in the management of AEs due to targeted agents still remains and could be the focus for further programs in this direction.
نوع الوثيقة: article in journal/newspaper
وصف الملف: application/pdf
اللغة: English
تدمد: 1471-2407
العلاقة: http://hdl.handle.net/10668/9857Test; PMC4763443; https://doi.org/10.1186/s12885-016-2084-9Test; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4763443/pdfTest
DOI: 10.1186/s12885-016-2084-9
الإتاحة: https://doi.org/10.1186/s12885-016-2084-9Test
http://hdl.handle.net/10668/9857Test
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4763443/pdfTest
حقوق: Attribution 4.0 International ; http://creativecommons.org/licenses/by/4.0Test/ ; open access
رقم الانضمام: edsbas.4477CF13
قاعدة البيانات: BASE
الوصف
تدمد:14712407
DOI:10.1186/s12885-016-2084-9